RedHill Biopharma (RDHL) Depreciation & Amortization (CF) (2012 - 2022)

RedHill Biopharma (RDHL) has 11 years of Depreciation & Amortization (CF) data on file, last reported at $491000.0 in Q4 2022.

• Depreciation & Amortization (CF) for Q4 2022 came in at $491000.0, up 9.35% year-over-year; the trailing twelve-month figure through Dec 2023 was $491000.0 (down 77.01% YoY), and the FY2025 annual result was $91000.0, up 193.55% from the prior year.
• Depreciation & Amortization (CF) steadied at $491000.0 in Q4 2022 per RDHL's latest filing, from $491000.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $617000.0 in Q2 2022 and troughed at $22000.0 in Q1 2018.
• A 5-year average of $342350.0 and a median of $433000.0 in 2020 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2018 and 2019: Depreciation & Amortization (CF) dropped 15.38% in 2018, then jumped 1209.09% in 2019.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $23000.0 in 2018, then soared by 1000.0% to $253000.0 in 2019, then surged by 86.96% to $473000.0 in 2020, then slipped by 5.07% to $449000.0 in 2021, then climbed by 9.35% to $491000.0 in 2022.
• Business Quant data shows RDHL's Depreciation & Amortization (CF) at $491000.0 in Q4 2022, $491000.0 in Q3 2022, and $617000.0 in Q2 2022.